A new promising drug to treat metastatic breast cancer was reported by a research team of the University of California Los Angeles (UCLA). The study entitled “The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomized phase 2 study” was published in The Lancet Oncology.
Many risk factors can contribute to the development of breast cancer, which can be based on biological markers such as the estrogen receptor-positive (ER) and the human protein growth factor receptor 2 (HER2).
The research team led by Professor Dennis Slamon, which established the successful breast cancer drug Herceptin, tested the safety and efficacy of a CDK4/6 inhibitor Ibrance (palbociclib – Pfizer) in combination with letrozole, an aromatase inhibitor that lowers estrogen levels, as first-line treatment of post-menopausal women with advanced, estrogen receptor-positive, HER2-negative breast cancer. Ibrance targets cyclin D kinase 4 (CDK 4) and cyclin D kinase 6 (CDK 6) present in cancer cells and inhibits their proliferation capacity.
Researchers observed that combination treatment considerably improved progression-free survival in women with advanced (ER+/ Her2-) breast cancer when compared to patients treated with letrozole only.
Importantly, based on this study’s results, the FDA decided to grant a breakthrough approval for the combination of palbociclib and letrozole in the treatment of (ER+/Her2-) post-menopausal patients as a first line therapy.
Dr. Slamon said in a news release that these results are extremely promising, as progression-free survival of the patients treated went from 10 to 20 months. Slamon also added that if these results are confirmed in Phase 3 clinical trials, palbociclib will “represent a new standard of care for women with ER+ breast cancer who have either developed de novo ER positive breast cancer to be treated with hormonal blockage and a CDK inhibitor, or for those women who develop a recurrence after treatment with hormonal blockade.”
Oncologist Dr. Michael Gnant from the Medical University of Vienna mentioned in a commentary that these findings are “among the largest benefits ever reported in advanced breast cancer, and these survival results are similar to the effect of everolimus in pretreated patients.”
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?